WHO Pharmaceuticals Newsletter 1999, No. 01&02
(1999; 16 pages)
Índice de contenido
Abrir esta carpeta y ver su contenidoRegulatory actions
Cerrar esta carpetaDrug surveillance
Ver el documentoAcarbose: hepatitis: France, Spain
Ver el documentoCorticosteroid-induced osteoporosis: guidelines available: UK
Ver el documentoHydroxycarbamide: leg ulcers: review: France
Ver el documentoMeasles/mumps/rubella (MMR) vaccine: no evidence of link with inflammatory bowel disease and/or autism: Ireland
Ver el documentoMercury compounds: call for data: USA
Ver el documentoNefazodone: review of adverse reactions: Australia
Ver el documentoOndansetron: chest pain: Australia
Ver el documentoPsorigon skin products: update: further analysis confirms tretinoin content: Germany
Abrir esta carpeta y ver su contenidoNew developments
Abrir esta carpeta y ver su contenidoGeneral information
Abrir esta carpeta y ver su contenidoMedication errors
Abrir esta carpeta y ver su contenidoVeterinary medicine
 

Measles/mumps/rubella (MMR) vaccine: no evidence of link with inflammatory bowel disease and/or autism: Ireland

Ireland. Concern has recently been expressed regarding a possible link between measles/mumps/rubella (MMR) vaccine and subsequent development of inflammatory bowel disease and/or autism in a very small number of children. The Irish Medicines Board has reviewed the available evidence and concluded that at present there is no evidence to support any link between the MMR vaccine and the subsequent development of either chronic inflammatory bowel disease or autism.

The MMR vaccine is highly effective and parents are strongly advised to continue to have their children immunized with this vaccine in accordance with current recommendations.

Reference: Irish Medicines Board, Drug Safety Newsletter, Issue No. 8, September 1998.

Ir a la sección anterior Ir a la siguiente sección
 

Última actualización: le 3 mayo 2013